Literature DB >> 30124581

The Iceberg Map of germline mutations in childhood cancer: focus on primary immunodeficiencies.

Oliver Kindler1, Franz Quehenberger2, Martin Benesch3, Markus G Seidel1,3.   

Abstract

PURPOSE OF REVIEW: The risk of cancer is higher, and its outcome is worse in patients with primary immunodeficiency (PID) than in members of the general population. Thus, the inter-relationship of malignant diseases with PIDs requires more study. RECENT
FINDINGS: Large genetic screens identified a vast number of germline mutations in childhood cancer patient samples. Although TP53 was the most frequent single gene identified as mutated, many PID disorders like DNA repair defects are among the inborn causes of childhood cancer. We provide a comprehensive analysis of compiled data from seven recent studies that focused on germline genetic landscapes and preexisting conditions in pediatric oncology. As potentially causal germline variants were identified in ≈8% of malignancies in children and adolescents, we visualized this proportion as the 'tips of the icebergs'. The results of additional network analyses showed the shared patterns of germline mutations in various malignancies and yielded a spatial distribution of the 'icebergs'.
SUMMARY: The 'iceberg map of germline mutations in childhood cancers' was created to increase the awareness of the inborn genetic underpinnings of childhood malignancies and their relationships with immunodeficiencies. Needs and perspectives of clinical immunologists and pediatric oncologists to both improve patient care and guide research at this critical interface are discussed. VIDEO ABSTRACT.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30124581     DOI: 10.1097/MOP.0000000000000680

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  6 in total

1.  Editorial: The Relationship Between Cancer Predisposition and Primary Immunodeficiency.

Authors:  Fabian Hauck; Andrew R Gennery; Markus G Seidel
Journal:  Front Immunol       Date:  2019-07-30       Impact factor: 7.561

2.  Unraveling the Genetic Architecture of Hepatoblastoma Risk: Birth Defects and Increased Burden of Germline Damaging Variants in Gastrointestinal/Renal Cancer Predisposition and DNA Repair Genes.

Authors:  Talita Aguiar; Anne Teixeira; Marília O Scliar; Juliana Sobral de Barros; Renan B Lemes; Silvia Souza; Giovanna Tolezano; Fernanda Santos; Israel Tojal; Monica Cypriano; Silvia Regina Caminada de Toledo; Eugênia Valadares; Raquel Borges Pinto; Osvaldo Afonso Pinto Artigalas; Joaquim Caetano de Aguirre Neto; Estela Novak; Lilian Maria Cristofani; Sofia M Miura Sugayama; Vicente Odone; Isabela Werneck Cunha; Cecilia Maria Lima da Costa; Carla Rosenberg; Ana Krepischi
Journal:  Front Genet       Date:  2022-04-12       Impact factor: 4.772

3.  Genomic crossroads between non-Hodgkin's lymphoma and common variable immunodeficiency.

Authors:  Kissy Guevara-Hoyer; Jesús Fuentes-Antrás; Eduardo de la Fuente-Muñoz; Miguel Fernández-Arquero; Fernando Solano; Pedro Pérez-Segura; Esmeralda Neves; Alberto Ocaña; Rebeca Pérez de Diego; Silvia Sánchez-Ramón
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

Review 4.  Diagnostic Strategies and Algorithms for Investigating Cancer Predisposition Syndromes in Children Presenting with Malignancy.

Authors:  Linda Rossini; Caterina Durante; Silvia Bresolin; Enrico Opocher; Antonio Marzollo; Alessandra Biffi
Journal:  Cancers (Basel)       Date:  2022-07-31       Impact factor: 6.575

5.  Peripheral-blood cytopenia, an early indicator of inborn errors of immunity.

Authors:  Helena M Cornelissen; Ernest M Musekwa; Richard H Glashoff; Monika Esser; Moleen Zunza; Deepthi R Abraham; Zivanai C Chapanduka
Journal:  Br J Haematol       Date:  2022-07-06       Impact factor: 8.615

Review 6.  The Possibilities of Immunotherapy for Children with Primary Immunodeficiencies Associated with Cancers.

Authors:  Frederic Baleydier; Fanette Bernard; Marc Ansari
Journal:  Biomolecules       Date:  2020-07-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.